About the Preventive and Public Health Research initiative
The Preventive and Public Health Research initiative will provide $596.5 million over 10 years between 2022-23 and 2031-32 towards research that tests innovative approaches to preventive and public health issues. It will fund targeted research into new ways to address risk factors for chronic and complex diseases in Australia.
This initiative will support projects that:
- identify and prioritise research that will most benefit patients and their families
- assess the effectiveness of drugs and interventions
- support the development and implementation of strategies and approaches for improving the health of pregnant women, mothers, and young children, particularly those focused on vulnerable populations
- support the development and implementation of strategies and approaches for addressing modifiable risk factors at key life stages
- improve the quality of care received by Australians living with chronic respiratory diseases and conditions.
In addition, the initiative will support:
- ongoing investments in the Targeted Translation Research Accelerator
- research on the safety, quality and effectiveness of medicines use and medicines interventions by pharmacists.
Why it is important
This initiative is important because it aims to:
- help research findings and evidence-based practice become part of routine practice
- improve health outcomes of people with complex and chronic conditions, particularly in disadvantaged regional and rural communities
- integrate research outcomes into community-based health services and support education programs.
The objective of this initiative is to support research into new ways to address risk factors for chronic and complex diseases in Australia.
Meeting our objectives
We will monitor the initiative in accordance with the principles and approach detailed in the MRFF Monitoring, evaluation and learning strategy.
Who we work with
The Medical Research Future Fund (MRFF) funds the initiative.
The Targeted Translation Research Accelerator Plan Expert Advisory Panel advised on diabetes and cardiovascular disease investments under this initiative.
The Health Technology (HTA) Chairs Committee advises on investments under the HTA stream of this initiative.
Our Health and Medical Research Office oversees this and other MRFF initiatives.
The National Health and Medical Research Council (NHMRC) and the Department of Industry, Science and Resources administer this initiative.
Apply for funding
View the MRFF grants calendar to see which grants are open, when applications close and when we expect to award funding.
Register with GrantConnect to receive notifications about future funding opportunities under this initiative.
For more information, contact us.